文献速递慢阻肺

气道平滑肌面积预测COPD患者对三联治疗中激素的反应性:HISTORIC随机对照试验

Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial.
PubMed 文献 · Eur Respir J · 2023-07-20

HISTORIC研究纳入190例GOLD B-D期COPD患者,经支气管镜活检按气道平滑肌细胞面积分为高面积组(>20%)和低面积组(≤20%),开放标签三联治疗6周后随机接受含或不含吸入激素的三联治疗12个月。低面积组加用激素未显著改善FEV1(p=0.675),高面积组加用激素显著改善FEV1(p=0.020)。

要点

  • 高气道平滑肌面积COPD患者加用吸入激素后FEV1显著改善。
  • 低气道平滑肌面积患者加用吸入激素未显著获益。
  • 组织学分析可能预测COPD患者对吸入激素的反应性。

核心结论

  • 高气道平滑肌面积的COPD患者对吸入激素的反应优于低面积患者。
  • 该组织学分析可能预测接受三联治疗的COPD患者对吸入激素的反应性。

研究设计与样本

  • 研究者发起的随机、双盲、安慰剂对照试验(HISTORIC)。
  • 纳入190例GOLD B-D期COPD患者,行支气管镜及支气管内活检。
  • 按气道平滑肌细胞面积>20%为高面积组、≤20%为低面积组。
  • 开放标签三联治疗(ACL/FOR/BUD 400/12/400 μg 每日两次)6周导入后随机分组治疗12个月。

主要发现

  • 低面积组中ACL/FOR/BUD对比ACL/FOR/安慰剂12个月FEV1无显著改善(p=0.675)。
  • 高面积组中ACL/FOR/BUD对比ACL/FOR/安慰剂FEV1显著改善(p=0.020)。
  • 12个月FEV1变化差值:低面积组50.6 mL·年-1,高面积组183.0 mL·年-1。

关键数值与推荐

  • 高气道平滑肌面积定义为>20%支气管组织面积,低面积定义为≤20%。
  • 主要终点为12个月支气管舒张后FEV1在低/高面积组接受或不接受ICS间的差异。

临床怎么用

  • 对COPD患者行支气管镜活检评估气道平滑肌面积可能辅助预测ICS反应性。
  • 高气道平滑肌面积患者接受含ICS三联治疗可能获得FEV1改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although inhaled corticosteroids (ICS) are highly effective in asthma, they provide significant, but modest, clinical benefit in COPD. Here, we tested the hypothesis that high bronchial airway smooth muscle cell (ASMC) area in COPD is associated with ICS responsiveness. METHODS: In this investigator-initiated and -driven, double-blind, randomised, placebo-controlled trial (HISTORIC), 190 COPD patients, Global Initiative for Chronic Obstructive Lung Disease stage B-D, underwent bronchoscopy with endobronchial biopsy. Patients were divided into groups A and B, with high ASMC area (HASMC: >20% of the bronchial tissue area) and low ASMC area (LASMC: ≤20% of the bronchial tissue area), respectively, and followed a run-in period of 6 weeks on open-label triple inhaled therapy with aclidinium (ACL)/formoterol (FOR)/budesonide (BUD) (400/12/400 μg twice daily). Subsequently, patients were randomised to receive either ACL/FOR/BUD or ACL/FOR/placebo and followed for 12 months. The primary end-point of the study was the difference in post-bronchodilator forced expiratory volume in 1 s (FEV1) over 12 months between patients with LASMC and HASMC receiving or not receiving ICS. RESULTS: In patients with LASMC, ACL/FOR/BUD did not significantly improve FEV1 over 12 months, as compared to ACL/FOR/placebo (p=0.675). However, in patients with HASMC, ACL/FOR/BUD significantly improved FEV1, as compared to ACL/FOR/placebo (p=0.020). Over 12 months, the difference of FEV1 change between the ACL/FOR/BUD group and the ACL/FOR/placebo group was 50.6 mL·year-1 within the group of patients with LASMC and 183.0 mL·year-1 within the group of patients with HASMC. CONCLUSION: COPD patients with ΗASMC respond better to ICS than patients with LASMC, suggesting that this type of histological analysis may predict ICS responsiveness in COPD patients receiving triple therapy.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Stolz D, Papakonstantinou E, Pascarella M, et al. Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial. Eur Respir J. 2023. PMID: 37385657. doi:10.1183/13993003.00218-2023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。